Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia

Study:

Multicenter, Double-blind, Randomized, Placebo-controlled, 5-period, 5-treatment Crossover, Dose-finding Study to Evaluate the Efficacy and Safety of Oral Administration of ACT-078573 in Elderly Subjects With Chronic Primary Insomnia

Rationale:

n/a

Purpose:

A 2-night polysomnography / 5-way cross-over study to evaluate the effect, safety and tolerability of oral administration of almorexant (ACT 078573) in elderly subjects with primary insomnia.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Chronic Primary Insomnia Drug: ACT-078573 oral capsules at 25 and 100 mg and matching placebo
Drug: ACT-078573 and matching placebo
Drug: ACT-078573 and matching placebo
Drug: ACT-078573 and matching placebo
Drug: ACT-078573 and matching placebo
Drug: ACT-078573 and matching placebo
Drug: ACT-078573 and matching placebo
Drug: ACT-078573 and matching placebo
Drug: ACT-078573 and matching placebo
Drug: ACT-078573 and matching placebo
Phase 2

Verified by Actelion February, 2013

Sponsored by: Actelion
Information provided by: Actelion
ClinicalTrials.gov identifier: NCT00606593

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Cleveland Clinic Health Systems
Cleveland, Ohio 44195
United States

James K. Walsh, PhD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site